ArticleUpdates in surgery2026
Robotic portal lymphadenectomy for biliary tract cancers.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The role of minimally invasive surgery (MIS) in the management of biliary tract cancers(BTCs) has long been a topic of debate. One of the primary concerns limiting the adoption of MIS for BTCs is the technical challenge of performing an adequate lymphadenectomy, which is essential for achieving oncologically sound resections. The robotic approach may overcomes some limitations of conventional laparoscopy,potentially expanding the indications for MIS in this setting. We retrospectively analyzed the clinicopathological, intraoperative, and postoperative outcomes of patients who underwent robotic liver resection with concomitant portal lymphadenectomy for BTCs between January 2018 and December 2024. A step-by step description (with video) of our standardized robotic portal lymph node dissection technique is also provided. Among 36 patients who underwent robotic liver resections for BTCs during the studyperiod 32 underwent an associated robotic portal lymphadenectomy. Mean operativetime was 205.67 minutes (range 90-390). Mean blood loss was 180.81 cc (range 30-600). Two patients developed postoperative complication Clavien Dindo > III that requirred a re-intervention. Mean lymph nodes yield was 13 (range 7-21), and all patients had more than 6 retrieved lymph nodes. Final pathology revealed nodal metastases in 11 patients (34.4%). Robotic portal lymphadenectomy for BTCs is a feasibile, and safe technique which can be technically standardized. The robotic approach for the treatment of selected BTCs can guarantees oncological adequacy both in terms of radical R0 liver resection and harvested nodes which was accomplished in all cases.
Indexed as
Identifiers
41697599What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.